M. Lupattelli et al., Short-course palliative radiotherapy in non-small-cell lung cancer - Results of a prospective study, AM J CL ONC, 23(1), 2000, pp. 89-93
Citations number
18
Categorie Soggetti
Oncology
Journal title
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
From February 1993 to October 1997, 91 consecutive patients with inoperable
(stage IIIB-IV) histologically confirmed nonsmall-cell lung cancer underwe
nt palliative hypofractionated radiotherapy. Recently, the Medical Research
Council studies on hypofractionated short-course radiotherapy (8.5 Gy x 2)
have reported high control of symptoms caused by thoracic disease without
toxicity. Based on these experiences and our previous positive trial on sho
rt-course radiotherapy (8 Gy x 2) in metastatic spinal cord compression, a
prospective study of short-course palliative radiotherapy in non-small-cell
lung cancer was carried out. The regimen was 16 Gy given in two 8-Gy fract
ions, 1 week apart. Eighty-one patients were evaluable for response to trea
tment. Forty-eight (59%) patients were 65 years or older. Forty (49%) patie
nts were naive to radiotherapy, whereas 41 (51%) had previous cisplatin-bas
ed chemotherapy. All but four stage IV patients (95%) had poor Eastern Coop
erative oncology Group performance status (i.e., 2-3). Clinical palliation
was achieved in 62 (77%) patients. Performance status improved in 59 (73%)
patients. The median palliation time ranged from 28% to 57% of patient surv
ival. The median survival from the beginning of treatment was 148 days (ran
ge, 5-681 days). No difference in overall survival according to stage and p
revious chemotherapy was observed. Only performance status conditioned surv
ival (performance status 1-2 vs. performance status 3; p = 0.0289). Short-c
ourse radiotherapy gave good results in terms of clinical palliation for th
oracic symptoms, even in patients with poor performance status and pretreat
ed with chemotherapy. The median palliation time was similar to 50% of pati
ent survival time. Treatment was generally well tolerated-only 4 (5%) patie
nts experienced World Health Organization grade III dysphagia. No late toxi
city was recorded. The two-fraction regimen had social and economic advanta
ges compared with the conventional ones.